

EBMT SURVEY ON TRANSPLANT AND CELLULAR THERAPY ACTIVITY 2023

Submissions are now given on the online form. You will have received a link to the form from EBMT. This sheet is only to help you count the numbers.

Table 1: Report the number of patients receiving their 1st allogeneic and/or 1st autologous transplant in 2023 in rows 1-32. Report non 1st HSCT in row 34. Light grey cells will be automatically calculated by the online form.

Table 2: Report the number of patients receiving non HSCT cellular therapies in 2023 by indication and cell type in rows 1-9.

Table 1:		HLA-id sibling			Twin		Haplo (≥ 2 loci mismatch)		Other family member			Unrelated			Autologous			Total Allo	Total Auto	Total HSCT	No. allo after auto				
		BM	PBSC	Cord	BM	PBSC	BM	PBSC	BM	PBSC	Cord	BM	PBSC	Cord	BM	PBSC	Cord								
1	AML 1st CR																								
2	AML non 1st CR																								
3	AML: therapy related																								
4	AML: MDS related changes																								
5	ALL 1st CR																								
6	ALL non 1st CR																								
7	CML 1st cP																								
8	CML non 1st cP																								
9	MDS or MDS/MPN																								
10	MPN																								
11	CLL incl. PLL																								
12	PCD - MM																								
13	PCD - other																								
14	Hodgkin Lymphoma																								
15	DLBCL NHL - all types																								
16	Other B-cell NHL																								
17	T-cell NHL																								
18	Solid Tumors - Neuroblastoma																								
19	Solid Tumors - Soft tissue																								
20	Solid Tumors - Ewing sarcoma																								
21	Solid Tumors - Germ cell tumor																								
22	Other solid tumors																								
23	BM aplasia - SAA																								
24	BM aplasia - other																								
25	Thalassemia																								
26	Sickle cell disease																								
27	Inborn Errors of Immunity																								
28	Inborn Errors of Metabolism																								
29	Autoimmune Diseases - MS																								
30	Autoimmune Diseases - SSC																								
31	Autoimmune Diseases - other																								
32	Others (incl. Histiocytosis)																								
33	Total 1st HSCT (=row 1-32)																								
34	Additional non 1st HSCT																			X					
35	Total all HSCT (=row 33+34)																								
36	No. patients aged <18 reported in row 1-32																								
37	Number of Non-Myeloablative (incl. RIC) allogeneic transplants in 2023																								
38	Total Number patients with unmanipulated DLI infusions in 2023:					For graft enhancement/failure:					For residual disease:					For relapse:					Per protocol:				
39	Total Number of patients receiving Immunosuppressive Treatments (IST) for Bone Marrow Failure Syndromes (acquired and congenital) in 2023:										For Aplastic Anemia (AA):					For other Bone Marrow Failure Syndromes:									
	Table 2: Number of patients with non HSCT cellular therapies using manipulated or selected cells (excluding DLI) in 2023		CAR T cells		selected/expanded T cells or CIK		Regulatory T cells (TREGS)		Other genetically modified T cells		NK cells		Dendritic cells		MSC		Expanded CD34+ cells		Genetically modified CD34+		Other therapies (incl. boosts)				
			Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto			
1	GvHD																								
2	Graft enhancement/failure																								
3	Autoimmune disease																								
4	Genetic disease																								
5	Infection																								
6	Malignancy - ALL																								
7	Malignancy - Lymphoma																								
8	Malignancy - Myeloma																								
9	Any other indication																								